146 related articles for article (PubMed ID: 36639036)
1. Synthesis and biological evaluation of novel SN38-glucose conjugate for colorectal cancer treatment.
Zhang R; Luo Y; Du C; Wu L; Wang Y; Chen Y; Li S; Jiang X; Xie Y
Bioorg Med Chem Lett; 2023 Feb; 81():129128. PubMed ID: 36639036
[TBL] [Abstract][Full Text] [Related]
2. A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer.
Huang Q; Liu X; Wang H; Liu X; Zhang Q; Li K; Chen Y; Zhu Q; Shen Y; Sui M
Acta Biomater; 2022 Jan; 137():262-275. PubMed ID: 34718178
[TBL] [Abstract][Full Text] [Related]
3. Single protein encapsulated SN38 for tumor-targeting treatment.
Yu C; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
J Transl Med; 2023 Dec; 21(1):897. PubMed ID: 38072965
[TBL] [Abstract][Full Text] [Related]
4. A novel irinotecan derivative ZBH-1207 with different anti-tumor mechanism from CPT-11 against colon cancer cells.
Zhao D; Wu D; Zhang G; Li Y; Shi W; Zhong B; Yu H
Mol Biol Rep; 2022 Sep; 49(9):8359-8368. PubMed ID: 35764749
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity.
Liu Y; Piao H; Gao Y; Xu C; Tian Y; Wang L; Liu J; Tang B; Zou M; Cheng G
Int J Nanomedicine; 2015; 10():2295-311. PubMed ID: 25848251
[TBL] [Abstract][Full Text] [Related]
6. Novel Hydrophilic Camptothecin Derivatives Conjugated to Branched Glycerol Trimer Suppress Tumor Growth without Causing Diarrhea in Murine Xenograft Models of Human Lung Cancer.
Tsuchihashi Y; Abe S; Miyamoto L; Tsunematsu H; Izumi T; Hatano A; Okuno H; Yamane M; Yasuoka T; Ikeda Y; Tsuchiya K
Mol Pharm; 2020 Apr; 17(4):1049-1058. PubMed ID: 32068412
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, characterization, and antitumor evaluation of the albumin-SN38 conjugate.
Yao Y; Su X; Xie Y; Wang Y; Kang T; Gou L; Yi C; Yang J
Anticancer Drugs; 2013 Mar; 24(3):270-7. PubMed ID: 23233044
[TBL] [Abstract][Full Text] [Related]
8. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Sapra P; Zhao H; Mehlig M; Malaby J; Kraft P; Longley C; Greenberger LM; Horak ID
Clin Cancer Res; 2008 Mar; 14(6):1888-96. PubMed ID: 18347192
[TBL] [Abstract][Full Text] [Related]
9. Hydrophobized SN38 to redox-hypersensitive nanorods for cancer therapy.
Zheng Y; Yan X; Wang Y; Duan X; Wang X; Chen C; Tian D; Luo Z; Zhang Z; Zeng Y
J Mater Chem B; 2019 Jan; 7(2):265-276. PubMed ID: 32254551
[TBL] [Abstract][Full Text] [Related]
10. Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies.
Liu H; Lu H; Liao L; Zhang X; Gong T; Zhang Z
Drug Deliv; 2015; 22(6):701-9. PubMed ID: 24625262
[TBL] [Abstract][Full Text] [Related]
11. Repurposing of camptothecin: An esterase-activatable prodrug delivered by a self-emulsifying formulation that improves efficacy in colorectal cancer.
Fang T; Ye Z; Chen X; Wang Y; Wan J; Wang H
Int J Pharm; 2021 Apr; 599():120399. PubMed ID: 33647408
[TBL] [Abstract][Full Text] [Related]
12. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X
Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086
[TBL] [Abstract][Full Text] [Related]
13. Redox responsive 7-ethyl-10-hydroxycamptothecin (SN38) lysophospholipid conjugate: synthesis, assembly and anticancer evaluation.
He W; Du Y; Wang T; Wang J; Cheng L; Li X
Int J Pharm; 2021 Sep; 606():120856. PubMed ID: 34229071
[TBL] [Abstract][Full Text] [Related]
14. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
[TBL] [Abstract][Full Text] [Related]
15. Advances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin.
Si J; Zhao X; Gao S; Huang D; Sui M
Int J Pharm; 2019 Sep; 568():118499. PubMed ID: 31299338
[TBL] [Abstract][Full Text] [Related]
16. Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer.
Osuga T; Takimoto R; Ono M; Hirakawa M; Yoshida M; Okagawa Y; Uemura N; Arihara Y; Sato Y; Tamura F; Sato T; Iyama S; Miyanishi K; Takada K; Hayashi T; Kobune M; Kato J
J Natl Cancer Inst; 2016 Sep; 108(9):. PubMed ID: 27628655
[TBL] [Abstract][Full Text] [Related]
17. Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.
Zhang H; Wang J; Mao W; Huang J; Wu X; Shen Y; Sui M
J Control Release; 2013 Mar; 166(2):147-58. PubMed ID: 23266448
[TBL] [Abstract][Full Text] [Related]
18. Solid lipid nanoparticles containing 7-ethyl-10-hydroxycamptothecin (SN38): Preparation, characterization, in vitro, and in vivo evaluations.
Mosallaei N; Mahmoudi A; Ghandehari H; Yellepeddi VK; Jaafari MR; Malaekeh-Nikouei B
Eur J Pharm Biopharm; 2016 Jul; 104():42-50. PubMed ID: 27108266
[TBL] [Abstract][Full Text] [Related]
19. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
[No Abstract] [Full Text] [Related]
20. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.
Zhao H; Rubio B; Sapra P; Wu D; Reddy P; Sai P; Martinez A; Gao Y; Lozanguiez Y; Longley C; Greenberger LM; Horak ID
Bioconjug Chem; 2008 Apr; 19(4):849-59. PubMed ID: 18370417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]